Cargando…

Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution

BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Masui, Toshihiko, Nagai, Kazuyuki, Anazawa, Takayuki, Sato, Asahi, Uchida, Yuichiro, Nakano, Kenzo, Yogo, Akitada, Kaneda, Akihiro, Nakamura, Naoto, Yoshimura, Michio, Mizowaki, Takashi, Uza, Norimitsu, Fukuda, Akihisa, Matsumoto, Shigemi, Kanai, Masashi, Isoda, Hiroyoshi, Mizumoto, Masaki, Seo, Satoru, Hata, Koichiro, Taura, Kojiro, Kawaguchi, Yoshiya, Takaori, Kyoichi, Uemoto, Shinji, Hatano, Etsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800301/
https://www.ncbi.nlm.nih.gov/pubmed/35093003
http://dx.doi.org/10.1186/s12885-022-09244-6
_version_ 1784642230508584960
author Masui, Toshihiko
Nagai, Kazuyuki
Anazawa, Takayuki
Sato, Asahi
Uchida, Yuichiro
Nakano, Kenzo
Yogo, Akitada
Kaneda, Akihiro
Nakamura, Naoto
Yoshimura, Michio
Mizowaki, Takashi
Uza, Norimitsu
Fukuda, Akihisa
Matsumoto, Shigemi
Kanai, Masashi
Isoda, Hiroyoshi
Mizumoto, Masaki
Seo, Satoru
Hata, Koichiro
Taura, Kojiro
Kawaguchi, Yoshiya
Takaori, Kyoichi
Uemoto, Shinji
Hatano, Etsuro
author_facet Masui, Toshihiko
Nagai, Kazuyuki
Anazawa, Takayuki
Sato, Asahi
Uchida, Yuichiro
Nakano, Kenzo
Yogo, Akitada
Kaneda, Akihiro
Nakamura, Naoto
Yoshimura, Michio
Mizowaki, Takashi
Uza, Norimitsu
Fukuda, Akihisa
Matsumoto, Shigemi
Kanai, Masashi
Isoda, Hiroyoshi
Mizumoto, Masaki
Seo, Satoru
Hata, Koichiro
Taura, Kojiro
Kawaguchi, Yoshiya
Takaori, Kyoichi
Uemoto, Shinji
Hatano, Etsuro
author_sort Masui, Toshihiko
collection PubMed
description BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). METHODS: A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. RESULTS: Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good therapeutic effect (Grade 1, 3.4%; Grade 2a, 31.0%; Grade 2b, 48.3%; Grade 3, 3.4%; Grade 4, 3.4%). Median disease-free survival was 15.5 months. Median overall survival in the whole cohort was 35.1 months. The only independent prognostic pre-NACIMRT factor identified was serum carbohydrate antigen 19–9 (CA19-9) > 400 U/ml before NACIMRT. CONCLUSIONS: NACIMRT showed preferable outcome without significant operative morbidity for BRPC-A patients. NACIMRT contributes to good local tumor control, but a high initial serum CA19-9 implies poor prognosis even after neoadjuvant treatment. TRIAL REGISTRATION: UMIN-CTR Clinical Trial: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011776 Registration number: UMIN000010113. Date of first registration: 01/03/2013,
format Online
Article
Text
id pubmed-8800301
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88003012022-02-02 Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution Masui, Toshihiko Nagai, Kazuyuki Anazawa, Takayuki Sato, Asahi Uchida, Yuichiro Nakano, Kenzo Yogo, Akitada Kaneda, Akihiro Nakamura, Naoto Yoshimura, Michio Mizowaki, Takashi Uza, Norimitsu Fukuda, Akihisa Matsumoto, Shigemi Kanai, Masashi Isoda, Hiroyoshi Mizumoto, Masaki Seo, Satoru Hata, Koichiro Taura, Kojiro Kawaguchi, Yoshiya Takaori, Kyoichi Uemoto, Shinji Hatano, Etsuro BMC Cancer Research BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). METHODS: A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. RESULTS: Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good therapeutic effect (Grade 1, 3.4%; Grade 2a, 31.0%; Grade 2b, 48.3%; Grade 3, 3.4%; Grade 4, 3.4%). Median disease-free survival was 15.5 months. Median overall survival in the whole cohort was 35.1 months. The only independent prognostic pre-NACIMRT factor identified was serum carbohydrate antigen 19–9 (CA19-9) > 400 U/ml before NACIMRT. CONCLUSIONS: NACIMRT showed preferable outcome without significant operative morbidity for BRPC-A patients. NACIMRT contributes to good local tumor control, but a high initial serum CA19-9 implies poor prognosis even after neoadjuvant treatment. TRIAL REGISTRATION: UMIN-CTR Clinical Trial: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011776 Registration number: UMIN000010113. Date of first registration: 01/03/2013, BioMed Central 2022-01-29 /pmc/articles/PMC8800301/ /pubmed/35093003 http://dx.doi.org/10.1186/s12885-022-09244-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Masui, Toshihiko
Nagai, Kazuyuki
Anazawa, Takayuki
Sato, Asahi
Uchida, Yuichiro
Nakano, Kenzo
Yogo, Akitada
Kaneda, Akihiro
Nakamura, Naoto
Yoshimura, Michio
Mizowaki, Takashi
Uza, Norimitsu
Fukuda, Akihisa
Matsumoto, Shigemi
Kanai, Masashi
Isoda, Hiroyoshi
Mizumoto, Masaki
Seo, Satoru
Hata, Koichiro
Taura, Kojiro
Kawaguchi, Yoshiya
Takaori, Kyoichi
Uemoto, Shinji
Hatano, Etsuro
Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title_full Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title_fullStr Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title_full_unstemmed Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title_short Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
title_sort impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase ii study in a single institution
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800301/
https://www.ncbi.nlm.nih.gov/pubmed/35093003
http://dx.doi.org/10.1186/s12885-022-09244-6
work_keys_str_mv AT masuitoshihiko impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT nagaikazuyuki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT anazawatakayuki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT satoasahi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT uchidayuichiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT nakanokenzo impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT yogoakitada impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT kanedaakihiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT nakamuranaoto impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT yoshimuramichio impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT mizowakitakashi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT uzanorimitsu impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT fukudaakihisa impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT matsumotoshigemi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT kanaimasashi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT isodahiroyoshi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT mizumotomasaki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT seosatoru impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT hatakoichiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT taurakojiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT kawaguchiyoshiya impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT takaorikyoichi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT uemotoshinji impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution
AT hatanoetsuro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution